Logo image of GERN

GERON CORP (GERN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GERN - US3741631036 - Common Stock

1.305 USD
+0.03 (+2.76%)
Last: 12/5/2025, 3:37:08 PM
Fundamental Rating

3

Taking everything into account, GERN scores 3 out of 10 in our fundamental rating. GERN was compared to 534 industry peers in the Biotechnology industry. GERN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GERN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year GERN has reported negative net income.
GERN had a negative operating cash flow in the past year.
In the past 5 years GERN always reported negative net income.
In the past 5 years GERN always reported negative operating cash flow.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

GERN has a Return On Assets of -14.04%. This is amongst the best in the industry. GERN outperforms 81.09% of its industry peers.
GERN's Return On Equity of -32.02% is fine compared to the rest of the industry. GERN outperforms 76.03% of its industry peers.
Industry RankSector Rank
ROA -14.04%
ROE -32.02%
ROIC N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

The Gross Margin of GERN (97.70%) is better than 97.19% of its industry peers.
GERN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

4

2. Health

2.1 Basic Checks

GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GERN has been increased compared to 1 year ago.
Compared to 5 years ago, GERN has more shares outstanding
Compared to 1 year ago, GERN has an improved debt to assets ratio.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

GERN has an Altman-Z score of -2.11. This is a bad value and indicates that GERN is not financially healthy and even has some risk of bankruptcy.
GERN has a Altman-Z score of -2.11. This is comparable to the rest of the industry: GERN outperforms 50.19% of its industry peers.
GERN has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
GERN has a worse Debt to Equity ratio (0.48) than 71.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z -2.11
ROIC/WACCN/A
WACC8.39%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 5.96 indicates that GERN has no problem at all paying its short term obligations.
GERN has a Current ratio of 5.96. This is in the better half of the industry: GERN outperforms 62.55% of its industry peers.
GERN has a Quick Ratio of 4.87. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
GERN's Quick ratio of 4.87 is in line compared to the rest of the industry. GERN outperforms 55.99% of its industry peers.
Industry RankSector Rank
Current Ratio 5.96
Quick Ratio 4.87
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

GERN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.50%, which is quite impressive.
GERN shows a strong growth in Revenue. In the last year, the Revenue has grown by 522.13%.
Measured over the past years, GERN shows a very strong growth in Revenue. The Revenue has been growing by 178.45% on average per year.
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)522.13%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%67.05%

3.2 Future

Based on estimates for the next years, GERN will show a very strong growth in Earnings Per Share. The EPS will grow by 22.47% on average per year.
GERN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 58.91% yearly.
EPS Next Y53.63%
EPS Next 2Y34.21%
EPS Next 3Y32.4%
EPS Next 5Y22.47%
Revenue Next Year170.1%
Revenue Next 2Y105.15%
Revenue Next 3Y82.03%
Revenue Next 5Y58.91%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.2 -0.2 0.4 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GERN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GERN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 0.3

4.3 Compensation for Growth

GERN's earnings are expected to grow with 32.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.21%
EPS Next 3Y32.4%

More info and screens

0

5. Dividend

5.1 Amount

GERN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GERON CORP

NASDAQ:GERN (12/5/2025, 3:37:08 PM)

1.305

+0.03 (+2.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners81.89%
Inst Owner Change-2.33%
Ins Owners0.08%
Ins Owner Change1.3%
Market Cap833.06M
Revenue(TTM)183.40M
Net Income(TTM)-79.64M
Analysts80
Price Target3.5 (168.2%)
Short Float %12.23%
Short Ratio10.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.29%
Min EPS beat(2)10.87%
Max EPS beat(2)35.71%
EPS beat(4)4
Avg EPS beat(4)20.57%
Min EPS beat(4)10.87%
Max EPS beat(4)35.71%
EPS beat(8)8
Avg EPS beat(8)20.89%
EPS beat(12)11
Avg EPS beat(12)19.53%
EPS beat(16)13
Avg EPS beat(16)15.92%
Revenue beat(2)1
Avg Revenue beat(2)-4.92%
Min Revenue beat(2)-12.44%
Max Revenue beat(2)2.61%
Revenue beat(4)2
Avg Revenue beat(4)-6.81%
Min Revenue beat(4)-19.48%
Max Revenue beat(4)2.61%
Revenue beat(8)5
Avg Revenue beat(8)159.07%
Revenue beat(12)6
Avg Revenue beat(12)107.74%
Revenue beat(16)9
Avg Revenue beat(16)189.91%
PT rev (1m)-5.42%
PT rev (3m)-5.42%
EPS NQ rev (1m)8.86%
EPS NQ rev (3m)-12.11%
EPS NY rev (1m)-7.79%
EPS NY rev (3m)-10.21%
Revenue NQ rev (1m)-15.76%
Revenue NQ rev (3m)-18.87%
Revenue NY rev (1m)-2.35%
Revenue NY rev (3m)-3.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.54
P/FCF N/A
P/OCF N/A
P/B 3.35
P/tB 3.35
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.29
BVpS0.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.04%
ROE -32.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.7%
FCFM N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.95%
Cap/Sales 0.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.96
Quick Ratio 4.87
Altman-Z -2.11
F-Score4
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)153.53%
Cap/Depr(5y)161.21%
Cap/Sales(3y)140.92%
Cap/Sales(5y)119.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y53.63%
EPS Next 2Y34.21%
EPS Next 3Y32.4%
EPS Next 5Y22.47%
Revenue 1Y (TTM)522.13%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%67.05%
Revenue Next Year170.1%
Revenue Next 2Y105.15%
Revenue Next 3Y82.03%
Revenue Next 5Y58.91%
EBIT growth 1Y69.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.52%
EBIT Next 3Y17.71%
EBIT Next 5YN/A
FCF growth 1Y18.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.91%
OCF growth 3YN/A
OCF growth 5YN/A

GERON CORP / GERN FAQ

Can you provide the ChartMill fundamental rating for GERON CORP?

ChartMill assigns a fundamental rating of 3 / 10 to GERN.


What is the valuation status for GERN stock?

ChartMill assigns a valuation rating of 1 / 10 to GERON CORP (GERN). This can be considered as Overvalued.


Can you provide the profitability details for GERON CORP?

GERON CORP (GERN) has a profitability rating of 2 / 10.


Can you provide the financial health for GERN stock?

The financial health rating of GERON CORP (GERN) is 4 / 10.


What is the earnings growth outlook for GERON CORP?

The Earnings per Share (EPS) of GERON CORP (GERN) is expected to grow by 53.63% in the next year.